

Supplementary Material

Suppl. Table S1 - Laboratory parameters (mean \pm SD) between baseline and 1-year post-EOT

Laboratory parameter	F3				Cirrhosis			
	Baseline	1-year post-EOT	n	p	Baseline	1-year post-EOT	n	p
Platelets/ mm ³	189 552 \pm 51 393	219 090 \pm 59 048	67	<0,001	131 536 \pm 60 324	148 536 \pm 71 003	125	<0,001
Total bilirubin, mg/dL	0,61 \pm 0,31	0,54 \pm 0,39	66	0,012	0,80 \pm 0,49	0,82 \pm 0,81	126	0,575
AST U/L	68,1 \pm 50,9	22,88 \pm 11,21	66	<0,001	77 \pm 47	27,26 \pm 13,89	125	<0,001
ALT U/L	99,5 \pm 110,3	21,23 \pm 13,43	66	<0,001	90,7 \pm 67,03	23,81 \pm 13,48	125	<0,001
ALP U/L	75,3 \pm 25,3	67,06 \pm 19,65	65	0,002	95,38 \pm 38,4	82,35 \pm 32,49	125	<0,001
Albumin, mg/dL	4,47 \pm 0,35	4,62 \pm 0,36	51	0,002	4,26 \pm 0,52	4,53 \pm 0,42	120	<0,001
INR	1,08 \pm 0,2	1,14 \pm 0,29	17	0,049	1,12 \pm 0,17	1,17 \pm 0,29	75	0,043
Creatinine, mg/dL	0,83 \pm 0,24	0,87 \pm 0,38	65	0,087	0,83 \pm 0,28	0,88 \pm 0,30	122	0,025
Glycose, mg/dL	100 \pm 37	97 \pm 23	62	0,384	108 \pm 40	105,75 \pm 36,18	122	0,558

Suppl. Table S2 - Liver decompensation events during follow-up

Liver decompensation	During treatment	Post-EOT		Outcome (n)	
	n (% cirrhotics)	n (% cirrhotics)	Post-EOT months (mean; SD)	During treatment	Post-EOT
Ascites					
de novo	2 (1,3)	9 (5,8)		2 Improvement/resolution	7 Improvement/resolution
worsening	2 (1,3)	2 (1,3)		1 Unchanged/worsening	2 Unchanged/worsening
total	4 (2,6)	11 (7,1)	13,4 (\pm 5,7)	1 Death (following new SBP)	1 Death (HCC progression) 1 TIPS
Hepatic Encephalopathy	1 (0,6)	3 (1,95)	19,7 (\pm 6,5)	1 Improvement/resolution	2 Improvement/resolution 1 Unchanged/worsening
Upper gastrointestinal variceal bleeding	-	3 (1,95)	18,9 (\pm 3,2)	-	3 Improvement/resolution